Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 19.27M P/E - EPS this Y - Ern Qtrly Grth -
Income -20.25M Forward P/E -2.11 EPS next Y - 50D Avg Chg -19.00%
Sales 570k PEG - EPS past 5Y - 200D Avg Chg -39.00%
Dividend N/A Price/Book 6.70 EPS next 5Y - 52W High Chg -80.00%
Recommedations 1.00 Quick Ratio 0.42 Shares Outstanding 1.58M 52W Low Chg 9.00%
Insider Own 6.77% ROA -246.44% Shares Float 591.01K Beta 0.70
Inst Own 41.70% ROE -1,405.34% Shares Shorted/Prior 16.23K/8.79K Price 0.29
Gross Margin - Profit Margin - Avg. Volume 207,593 Target Price -
Oper. Margin -4,014.91% Earnings Date May 13 Volume 40,827 Change 0.27%
About Vaccinex, Inc.

Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. It is developing Pepinemab, which is in phase 2 study for treatment of Alzheimer's disease and has completed phase 2 study for treatment of Huntington's disease; Pepinemab in combination with Pembrolizumab in phase 2 study for head and neck cancer, Avelumab in phase 2 study for pancreatic cancer, and completed phase 2 study with Avelumab for non-small cell lung cancer; and Pepinemab in combination with Nivolumab completed phase 2 study for melanoma, and trastuzumab and DC vaccine in phase 2 study for breast cancer. The company has also developed ActivMAb, an antibody drug discovery platform based on a novel method for complex targets, such as multi-pass membrane receptors or large and diverse libraries of full-length human monoclonal antibodies on the surface of pox viruses. It has collaborations with Merck Sharp & Dohme; Ares Trading S.A.; The Children's Hospital of Philadelphia; Emory University; Huntington Study Group; H. Lee Moffitt Cancer Center and Research Institute, Inc; Catalent Pharma Solutions, LLC; Surface Oncology, Inc.; and Pharmaceutical and Biotech Co. The company was incorporated in 2001 and is headquartered in Rochester, New York.

Vaccinex, Inc. News
04/02/24 Vaccinex Reports 2023 Financial Results and Provides Corporate Update
03/27/24 Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
02/21/24 Vaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus Technology
02/15/24 Vaccinex, Inc. Announces Reverse Stock Split
02/12/24 Steven Cohen's Point72 Asset Management Acquires New Stake in Vaccinex Inc
02/07/24 Vaccinex Announces Pricing of $3.7 Million PIPE Financing
12/04/23 Nasdaq Grants Vaccinex Extension Until March 4, 2024 to Regain Compliance with Listing Rule
11/13/23 Vaccinex Reports Third Quarter 2023 Financial Results and Provides Corporate Update
10/31/23 Vaccinex Reports Clinical Benefit in Interim Analyses from two Phase 2 Studies of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting
10/26/23 Vaccinex Reports Positive Effect of Pepinemab Treatment on New Biomarker of Brain Inflammation in Neurodegenerative Diseases
09/28/23 Vaccinex Announces Pricing of $9.6 Million Public Offering
09/28/23 Vaccinex’s Next Generation ActivMAb® Technology Published in mAbs, a Leading Biotech Journal, and Validated in OmniAb Proof-of-Concept Collaboration
09/27/23 Vaccinex to Present Update on PDAC/Pepinemab Study; New ActivMAb® Application
09/26/23 Vaccinex Reports Groundbreaking Findings at Medical Conferences Supporting Development of Pepinemab for the Treatment of Neurodegenerative Diseases and Cancer
08/14/23 Vaccinex Reports Second Quarter 2023 Financial Results and Provides Corporate Update
06/01/23 Vaccinex, Inc. to Participate in the Jefferies Healthcare Conference Track 6, on Friday, June 9, 2023 at 10:00 to 10:25 a.m. ET
05/15/23 Vaccinex Reports First Quarter 2023 Financial Results and Provides Corporate Update
VCNX Chatroom

User Image Oxinternet Posted - 1 hour ago

$VCNX So quiet here.

User Image xbizo Posted - 9 hours ago

$VCNX I just want lower prices, myself. Tuck a few thousand shares away and wait on September results. Then there is the ActivMAb platform, which very well could be worth $1B alone. (Catulent was bought for $17B for their multiple biologics platforms. )

User Image StockMET Posted - 11 hours ago

$VCNX let’s finish the week strong 💪🏼

User Image SmallTimer7 Posted - 1 day ago

$VCNX Another presentation scheduled 5/18 - I wonder if they’ll be presenting as a delisted company or not 🤣

User Image Oxinternet Posted - 1 day ago

$VCNX Definitely getting eyes 👀 on this now. It’s a no brainer.

User Image Pbonk Posted - 2 days ago

$VCNX Doesnt matter what the price is when Merck comes out and says $1.5 Billion plus royalties, etc. Then you just divide the outstanding shares for the price.

User Image DustyCrevice Posted - 2 days ago

$VCNX @ProjectIcarus SLS today was a great example of why resistance is futile. Again everyone is free to do what they want but yall could be buying 2 shares for every one you have if you just went along with the flow and just let the game play out. For over a year I've been referring to my market activity as being a remora lol. You can't beat the sharks, just swim with them and definitely not against them.

User Image DenimChicken219 Posted - 2 days ago

$VCNX I’ll get excited when the price movement is real

User Image RollingDollar Posted - 2 days ago

$VCNX

User Image Oxinternet Posted - 2 days ago

$VCNX Seems to have stopped updating the stock price on here and Webull. Very strange 😬

User Image Dollarking Posted - 2 days ago

$VCNX

User Image RollingDollar Posted - 2 days ago

$VCNX 😎

User Image Oxinternet Posted - 2 days ago

$VCNX $7.80. You’re welcome 😂

User Image Oxinternet Posted - 04/30/24

$VCNX Give me 5.87 baby!

User Image Oxinternet Posted - 04/30/24

$VCNX I’d rather be at $8-14 before any news drops because when it does shorts will try to destroy it once it spikes.

User Image StocksSchmocks Posted - 04/30/24

$VCNX added more here. Won't be long before this hits 8 again. Even 8 is undervalued, but it's a start.

User Image ProjectIcarus Posted - 04/30/24

$VCNX If this headed for buyout like you have claimed repeatedly, I am not going to balk at paying a small premium for shares at less than what Insiders/Tutes have payed. Get off your high horse. Just because your SLS took a dive yesterday, don’t be butt hurt here

User Image StockMET Posted - 04/30/24

$VCNX dirt cheap low floater 💣⏰ volume is in

User Image DustyCrevice Posted - 04/30/24

$VCNX you guys really are not accomplishing anything with this other than raising your average needlessly lol.

User Image RollingDollar Posted - 04/30/24

$VCNX

User Image RollingDollar Posted - 04/30/24

$VCNX

User Image ProjectIcarus Posted - 04/29/24

$VCNX Be back at you in the AM with some fresh, dry powder. Accumulation is the name of the game. Armistice isn’t selling for a loss. AIGH Capital is not selling for a loss. 72Point is not selling for a loss. A few measly retail are able to move this stock 20% with a few hundred bucks. Just imagine what happens when any sort of news hits.

User Image investoraaa1 Posted - 04/29/24

$VCNX If we start seeing high volume this gonna rocket up!

User Image SmallTimer7 Posted - 04/29/24

$VCNX Got some more down here. Saving the rest of ammo to mess with AH

User Image xbizo Posted - 04/29/24

Just a guess, but I say $VCNX buy out at year end because big drug companies have a pattern of buying their targets after phase 2. It is an R&D de-risking strategy they use to protect against the high failure rate while still getting the biggest gain after phase 3. Also, many M&A deals are closed on December 31

User Image xbizo Posted - 04/28/24

$VCNX Buy out after phase 2 by end of year. The price depends on how good the insiders are at negotiating, but I expect a floor of $200 million or $100 per share.

User Image StocksSchmocks Posted - 04/28/24

$PTPI $VCNX $QH $BBAI 4 swings that take a bit of patience. Holding all 4 with confidence.

User Image ProjectIcarus Posted - 04/27/24

$VCNX For those that are unfamiliar, a form S3 clears a company that has bought an offering (in this case Armistice) to sell shares it has purchased from VCNX on the open market. You have to meet certain criteria to do this, but almost all funds do. This isn’t anything that we already didn’t know - VCNX offered these back in 27MAR24 and they were purchased. This does not impact Outstanding Share count. We are in the same place we have been since that date. What this does mean is that groups like 72Capital and Armistice are doing is positioning themselves to sell. Why though? Do they plan to sell for a loss? We are lower than the original purchase price of 7.59 (if memory serves). Unlikely. What is more likely is they know a catalyst is near that will cause a surge in Share Price and want to be able to offload when that happens.

User Image Oxinternet Posted - 04/26/24

$VCNX Why do they keep doing ABSOLUTE MINIMAL offerings? I’ll hedge a bet as to why… Firstly, they don’t want to dilute their own massive investment in the company too much. Secondly, because they only need small amounts to keep tiding themselves over until either a buyout negotiation is completed or trial data comes in. If this was about greed, they wouldn’t have invested their own money, and the offering would be 10m. It’s bloody obvious to me, they’re stalling for time for a massive catalyst that’s due very, very soon. I’d love to hear a bear counter argument.

User Image DonCorleone77 Posted - 04/26/24

$VCNX Vaccinex files to sell 193,000 shares of common stock for holders

Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Zauderer Maurice President and CEO President and CEO Oct 03 Buy 0.97 510,000 494,700 22,116 10/05/23
FRIEDBERG ALBERT Director Director Oct 03 Buy 1.0 3,000,000 3,000,000 4,747,794 10/05/23
Frieberg Jacob B. Director Director Jan 27 Buy 1.11 90,090 100,000 94,510 01/31/22
FRIEDBERG ALBERT Director Director Jan 27 Buy 1.11 3,603,602 3,999,998 11,580,436 01/31/22
Zauderer Maurice President and CEO President and CEO Jan 27 Buy 1.11 1,801,801 1,999,999 2,899,554 01/31/22